Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1300

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Ziftomenib
DRUG: Placebo
DRUG: Venetoclax
DRUG: Azacitidine (AZA)
DRUG: Daunorubicin
DRUG: Cytarabine (Ara-C)

Sponsor

Kura Oncology, Inc.